Evidence map›Paper›PMID 28548122›Full record

GuidelineModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2017

Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016.

Alessandro Lugli, Richard Kirsch, Yoichi Ajioka, Fred Bosman, Gieri Cathomas, Heather Dawson, Hala El Zimaity, Jean-François Fléjou, Tine Plato Hansen, Arndt Hartmann and 14 more

Open access · bronzeAbstract readConsensus StatementPractice GuidelineReview
PubMed Publisher
In one paragraph

Guideline in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 566 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
566citing papers in PubMed, 5 pooled it
32.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

566 citing papers in PubMed, 5 syntheses or guidelines pooled it, 1,112 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. SEOM-GEMCAD-TTD clinical guidelines for the adjuvant treatment of colon cancer (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Guideline
  5. Pooled it
  6. Article
  7. Preoperative [European radiology · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

506 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 20 institutions in 12 countries.

Alessandro LugliInstitute of Pathology, University of Bern, Bern, Switzerland.
Richard KirschPathology and Laboratory Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
Yoichi AjiokaDivision of Molecular and Diagnostic Pathology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Fred BosmanUniversity Institute of Pathology, Lausanne University Medical Center, Lausanne, Switzerland.
Gieri CathomasInstitute of Pathology, Kantonsspital Liestal, Liestal, Switzerland.
Heather DawsonInstitute of Pathology, University of Bern, Bern, Switzerland.
Hala El ZimaityDynacare Laboratory, Brampton, Ontario, Canada.
Jean-François FléjouPathology Department, Saint-Antoine Hospital, Pierre et Marie Curie University, Paris, France.
Tine Plato HansenDepartment of Pathology, Copenhagen University Hospital, Herlev, Denmark.
Arndt HartmannDepartment of Pathology, University Hospital Erlangen, Erlangen, Germany.
Sanjay KakarDepartment of Anatomic Pathology, University of California, San Francisco, CA, USA.
Cord LangnerInstitute of Pathology, Medical University of Graz, Graz, Austria.
Iris NagtegaalDepartment of Pathology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Giacomo PuppaDepartment of Clinical Pathology, Geneva University Hospital, Geneva, Switzerland.
Robert RiddellPathology and Laboratory Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
Ari RistimäkiDepartment of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Kieran SheahanDepartment of Pathology, St Vincent's University Hospital, Dublin, Ireland.
Thomas SmyrkDivisions of Anatomic Pathology and Mayo Clinic, Rochester, MN, USA.
Kenichi SugiharaDepartment of Surgical Oncology, Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Bunkyo-ku, Tokyo, Japan.
Benoît TerrisPathology Department, Hôpital Cochin and Université Paris Descartes Sorbonne Paris Cité, Paris, France.
Hideki UenoDepartment of Surgery, National Defense Medical College, Tokorozawa, Saitama, Japan.
Michael ViethInstitute of Pathology, Klinikum Bayreuth, Bayreuth, Germany.
Inti ZlobecInstitute of Pathology, University of Bern, Bern, Switzerland.
Phil QuirkePathology and Tumour Biology, University of Leeds, St James's University Hospital, Leeds, UK.
University of Bern · CHMount Sinai Hospital · CABayreuth Medical Center · DEBrampton Civic Hospital · CADélégation Paris 5 · FRHerlev Hospital · DKKantonsspital Baselland · CHMayo Clinic in Arizona · USMedical University of Graz · ATNational Defense Medical College · JPNiigata University · JPRadboud University Nijmegen · NLSorbonne Université · FRSt. Vincent's University Hospital · IETokyo Medical and Dental University · JPUniversitätsklinikum Erlangen · DEUniversity Hospital of Geneva · CHUniversity of California, San Francisco · USUniversity of Helsinki · FIUniversity of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor budding is a well-established independent prognostic factor in colorectal cancer but a standardized method for its assessment has been lacking. The primary aim of the International Tumor Budding Consensus Conference (ITBCC) was to reach agreement on an international, evidence-based standardized scoring system for tumor budding in colorectal cancer. The ITBCC included nine sessions with presentations, a pre-meeting survey and an e-book covering the key publications on tumor budding in colorectal cancer. The 'Grading of Recommendation Assessment, Development and Evaluation' method was used to determine the strength of recommendations and quality of evidence. The following 10 statements achieved consensus: tumor budding is defined as a single tumor cell or a cell cluster consisting of four tumor cells or less (22/22, 100%). Tumor budding is an independent predictor of lymph node metastases in pT1 colorectal cancer (23/23, 100%). Tumor budding is an independent predictor of survival in stage II colorectal cancer (23/23, 100%). Tumor budding should be taken into account along with other clinicopathological features in a multidisciplinary setting (23/23, 100%). Tumor budding is counted on H&E (19/22, 86%). Intratumoral budding exists in colorectal cancer and has been shown to be related to lymph node metastasis (22/22, 100%). Tumor budding is assessed in one hotspot (in a field measuring 0.785 mm

Indexed as

Cell MovementBiopsyColorectal NeoplasmsConsensusHumansLymphatic MetastasisNeoplasm InvasivenessNeoplasm StagingPathology, ClinicalPredictive Value of Tests

Identifiers

PMID28548122
OpenAlexW2620163964

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.